SOURCE: CTD Holdings, Inc.

CTD Holdings, Inc.

April 12, 2010 08:00 ET

CTD Holdings, Inc. Introduces NanoSonic Products, a Subsidiary to European Union

HIGH SPRINGS, FL--(Marketwire - April 12, 2010) -  CTD Holdings, Inc. (OTCBB: CTDH) (FRANKFURT: CDJ) introduces NanoSonic Products, a subsidiary to Europe.

Dr. Jeffrey Tate (Pres/COO of NSP) has been invited to present at the biennial International Cyclodextrin World Symposium in Vienna, Austria this May.

Dr. Tate will show both the scientists and the industrialists at the symposium in his presentation that the combination of Pulse Combustion Drying (PCD) and CD's will rectify the historical supply and demand anomalies of the CD industry; and at the same time assure pharmaceutical/nutriceutical formulators that water soluble Active Pharmaceutical ingredients (API) can now be made available in useful commercial quantities at reasonable prices.

"Dr. Tate has put the chemical engineering piece into the CD puzzle," stated Rick Strattan, CEO/Chairman of CTDH.

Dr. Tate and Mr. Strattan will be meeting with a chemical engineer and Vice Rector of Science at the Technical University of Lodz in Poland, Dr. Irek Zbicinski, to discuss the possible creation of an EU consortium to study the properties of CD complexes made using PCD.

"Our visit will also be an excellent opportunity, time permitting, for us to meet selected European investment bankers to begin the process of reintroducing CTDH to the European investment community," added Mr. Strattan.

About CTD Holdings, Inc.

The company is the one-stop shop, business-to-business facilitator of commercial and research applications of Cyclodextrins. With its branded Trappsol®, Aquaplex® and Cyclo™ product offerings, CTDH scientists coordinate the development of commercial products for use in the pharmaceuticals, foods, hazardous waste treatment, and cosmetics industries, which allow non-water soluble ingredients to work in just water. More recently CTDH has worked, in an advisory capacity, on the benefits and application of Cyclodextrins as a treatment for Niemann Pick C disease, a debilitating childhood disease often called Childhood Alzheimer's. More information about the company is available on the company's website:

This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH complies with the regulations and time lines mandated by the SEC in the filing of its financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc. accepts no specific responsibility for updating such statements.

Contact Information

  • Contact:
    Rick Strattan